The Drugs for Neglected Diseases initiative (DNDi) and the Global Antibiotic Research & Development Partnership (GARDP) have issued a call for nominations for a new Board member who would also serve as Treasurer of the Board. The successful candidate would initially be a member and Treasurer only for DNDi’s Board of Directors, which currently oversees GARDP activities, and from 2019 when the GARDP Board of Directors becomes active, would become Treasurer for the Boards of both organizations.
Board members serve in an honorary capacity. The closing date for applications is 3 June 2018.
For more information and to apply, please see the call for nominations.
About DNDi & GARDP
DNDi is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases. Established in 2003, the Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit research and development (R&D) organization that develops new, improved, and affordable medicines for deadly neglected diseases that afflict millions of the world’s poorest people. DNDi focuses on discovering and developing treatments for sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, filarial infections, paediatric HIV, mycetoma, and hepatitis C. Since its inception, DNDi has developed seven new treatments for neglected patients and has developed a robust R&D pipeline including new drug candidates. www.dndi.org
In 2016, in collaboration with the World Health Organization, DNDi launched the Global Antibiotic Research and Development Partnership, a not-for-profit research and development organization that addresses global public health needs by developing and delivering new or improved antibiotic treatments addressing antimicrobial resistance, and promotes their responsible use for optimal conservation, while ensuring equitable access for all. GARDP is part of the implementation of the Global Action Plan on Antimicrobial Resistance that calls for new public-private partnerships for encouraging research and development of new antimicrobial agents and diagnostics. GARDP is currently hosted by DNDi in its start-up phase, which will end in December 2018. https://www.gardp.org/
As part of the hosting arrangement, the DNDi Board of Directors oversees GARDP activities, with expert advice from GARDP Scientific Advisory Committee.